Similar articles for PMID: 17138746

Year	Number of Results
1983	1
1989	1
1994	1
1995	1
1996	2
1997	2
1999	1
2000	3
2001	2
2002	1
2003	4
2004	21
2005	8
2006	6
2007	10
2008	7
2009	9
2010	12
2011	14
2012	27
2013	15
2014	23
2015	18
2016	18
2017	20
2018	20
2019	21
2020	25
2021	8

1

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. Wild D, et al. J Nucl Med. 2006 Dec;47(12):2025-33. J Nucl Med. 2006. PMID: 17138746 Free article.

2

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. Wicki A, et al. Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965. Clin Cancer Res. 2007. PMID: 17575235 Free article.

3

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR. Wild D, et al. J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914. J Nucl Med. 2010. PMID: 20595511 Free article.

4

Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.

Bauman A, Valverde IE, Fischer CA, Vomstein S, Mindt TL. Bauman A, et al. J Nucl Med. 2015 Oct;56(10):1569-74. doi: 10.2967/jnumed.115.159186. Epub 2015 Aug 6. J Nucl Med. 2015. PMID: 26251418 Free article.

5

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.

Rylova SN, Waser B, Del Pozzo L, Tönnesmann R, Mansi R, Meyer PT, Reubi JC, Maecke HR. Rylova SN, et al. J Nucl Med. 2016 Aug;57(8):1282-8. doi: 10.2967/jnumed.115.168948. Epub 2016 Apr 28. J Nucl Med. 2016. PMID: 27127218 Free article.

6

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.

Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. Brom M, et al. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1345-55. doi: 10.1007/s00259-009-1363-y. Epub 2010 Jan 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20111963 Free PMC article.

7

Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.

Läppchen T, Tönnesmann R, Eersels J, Meyer PT, Maecke HR, Rylova SN. Läppchen T, et al. PLoS One. 2017 Jan 19;12(1):e0170435. doi: 10.1371/journal.pone.0170435. eCollection 2017. PLoS One. 2017. PMID: 28103285 Free PMC article.

8

Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.

Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Brom M, et al. Contrast Media Mol Imaging. 2012 Mar-Apr;7(2):160-6. doi: 10.1002/cmmi.475. Contrast Media Mol Imaging. 2012. PMID: 22434628 Free PMC article.

9

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G. Wicki A, et al. EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9. EJNMMI Res. 2014. PMID: 24528513 Free PMC article.

10

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F. Christ E, et al. Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22. doi: 10.1016/S2213-8587(13)70049-4. Epub 2013 Jul 25. Lancet Diabetes Endocrinol. 2013. PMID: 24622317 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed